poractant alfa (Rx)

  • Print
Brand and Other Names:Curosurf

Dosing & Uses

AdultPediatric

Not indicated

Dosage Forms & Strengths

intratracheal suspension

  • 8mg/mL (1.5mL, 3mL)
more...

Respiratory Distress Syndrome

Prevention: 1.25-2.5 mL/kg once within 15 min of birth; administer additional doses only in infants who continue to require mechanical ventilation and supplemental oxygen

Treatment: 2.5 mL/kg birth weight intratracheal, THEN 1.25 mL/kg q12hr two times PRN (not to exceed 5 mL/kg total); administer additional doses only in infants who continue to require mechanical ventilation and supplemental oxygen

Administration

Instill thru 5 French endhole catheter inserted into (but not beyond distal tip of) ETT

Ensure proper placeent and patancy of the endotracheal tube before administering

May suction endotracheal tube before administering poractant alpha

Each dose instilled as 2 half-doses, with body in different positions to assure adequate distribution

Store vials in fridge, slowly warm to room temp (no artificial warming); invert to mix (no shaking!), discard vial after single use

Next:

Adverse Effects

Frequency Not Defined

Transient bradycardia

Hypotension

Oxygen desaturation

ETT blockage

Reflux

Airway obstruction

Hypoxia

Pulmonary hemorrhage

Previous
Next:

Warnings

Contraindications

None listed by the manufacturer

Cautions

Pulmonary hemorrhage may occur in premature birth and very low birth-weight

Rales, moist breathing sounds may occur normally with administration

Infant may exhibit bradycardia, reflux, cyanosis, airway obstruction

Use for intratracheal administration only

Correct hypotension, hypothermia, hypoglycemia, acidosis, and anemia before use

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: Not applicable

Lactation: Not applicable

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Replaces deficient endogenous lung surfactant in neonates with respiratory distress syndrome

Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between alveolar surfaces and air

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous